JP2022523740A5 - - Google Patents
Info
- Publication number
- JP2022523740A5 JP2022523740A5 JP2021544783A JP2021544783A JP2022523740A5 JP 2022523740 A5 JP2022523740 A5 JP 2022523740A5 JP 2021544783 A JP2021544783 A JP 2021544783A JP 2021544783 A JP2021544783 A JP 2021544783A JP 2022523740 A5 JP2022523740 A5 JP 2022523740A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- seq
- amino acid
- acid sequence
- immunoconjugate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025003041A JP2025061126A (ja) | 2019-02-01 | 2025-01-08 | Ｒｏｒ１抗体イムノコンジュゲートによる癌の治療 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962800187P | 2019-02-01 | 2019-02-01 | |
| US62/800,187 | 2019-02-01 | ||
| PCT/US2020/016301 WO2020160527A1 (en) | 2019-02-01 | 2020-02-01 | Cancer treatment with ror1 antibody immunoconjugates |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025003041A Division JP2025061126A (ja) | 2019-02-01 | 2025-01-08 | Ｒｏｒ１抗体イムノコンジュゲートによる癌の治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022523740A JP2022523740A (ja) | 2022-04-26 |
| JP2022523740A5 true JP2022523740A5 (https=) | 2023-02-07 |
Family
ID=69740792
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021544783A Pending JP2022523740A (ja) | 2019-02-01 | 2020-02-01 | Ｒｏｒ１抗体イムノコンジュゲートによる癌の治療 |
| JP2025003041A Pending JP2025061126A (ja) | 2019-02-01 | 2025-01-08 | Ｒｏｒ１抗体イムノコンジュゲートによる癌の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025003041A Pending JP2025061126A (ja) | 2019-02-01 | 2025-01-08 | Ｒｏｒ１抗体イムノコンジュゲートによる癌の治療 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220152214A1 (https=) |
| EP (1) | EP3917578A1 (https=) |
| JP (2) | JP2022523740A (https=) |
| KR (1) | KR20210142609A (https=) |
| CN (1) | CN113631195A (https=) |
| AU (2) | AU2020216491A1 (https=) |
| BR (1) | BR112021015036A2 (https=) |
| CA (1) | CA3128373A1 (https=) |
| MX (1) | MX2021009239A (https=) |
| TW (1) | TW202045209A (https=) |
| WO (1) | WO2020160527A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018289581C1 (en) | 2017-06-23 | 2025-01-30 | VelosBio Inc. | ROR1 antibody immunoconjugates |
| US12144827B2 (en) | 2021-02-25 | 2024-11-19 | Lyell Immunopharma, Inc. | ROR1 targeting chimeric antigen receptor |
| US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
| TW202320858A (zh) | 2021-07-19 | 2023-06-01 | 美商薩諾管理公司 | 免疫接合物及方法 |
| IL312204A (en) | 2021-10-28 | 2024-06-01 | Lyell Immunopharma Inc | Methods for culturing cells expressing ror1-binding protein |
| CN120129697A (zh) * | 2022-06-28 | 2025-06-10 | 英克特诺治疗公司 | 抗体制剂 |
| CN119907807A (zh) * | 2022-08-11 | 2025-04-29 | 翰森生物有限责任公司 | 配体-细胞毒性药物偶联物及其药物用途 |
| WO2024064952A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells overexpressing c-jun |
| WO2024064958A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| WO2024077174A1 (en) | 2022-10-05 | 2024-04-11 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| CN117164701A (zh) * | 2022-12-27 | 2023-12-05 | 优洛生物(上海)有限公司 | 一种经改造的抗体、其制备方法及其用途 |
| WO2025217398A1 (en) | 2024-04-10 | 2025-10-16 | Lyell Immunopharma, Inc. | Methods for culturing cells with improved culture medium |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107753954A (zh) * | 2012-12-13 | 2018-03-06 | 免疫医疗公司 | 功效改进且毒性降低的抗体与sn‑38的免疫缀合物的剂量 |
| AU2016274989A1 (en) * | 2015-06-12 | 2017-11-02 | Immunomedics, Inc. | Disease therapy with chimeric antigen receptor (car) constructs and t cells (car-t) or nk cells (car-nk) expressing car constructs |
| UA125718C2 (uk) * | 2016-01-20 | 2022-05-25 | Зе Скріппс Ресеарч Інстітьют | Композиції антитіл до ror1 і пов'язані з ними способи |
| AU2018289581C1 (en) * | 2017-06-23 | 2025-01-30 | VelosBio Inc. | ROR1 antibody immunoconjugates |
| GB201721802D0 (en) * | 2017-12-22 | 2018-02-07 | Almac Discovery Ltd | Ror1-specific antigen binding molecules |
-
2020
- 2020-02-01 AU AU2020216491A patent/AU2020216491A1/en not_active Abandoned
- 2020-02-01 CA CA3128373A patent/CA3128373A1/en active Pending
- 2020-02-01 US US17/426,830 patent/US20220152214A1/en active Pending
- 2020-02-01 WO PCT/US2020/016301 patent/WO2020160527A1/en not_active Ceased
- 2020-02-01 EP EP20709001.0A patent/EP3917578A1/en active Pending
- 2020-02-01 JP JP2021544783A patent/JP2022523740A/ja active Pending
- 2020-02-01 KR KR1020217027967A patent/KR20210142609A/ko active Pending
- 2020-02-01 BR BR112021015036A patent/BR112021015036A2/pt unknown
- 2020-02-01 MX MX2021009239A patent/MX2021009239A/es unknown
- 2020-02-01 CN CN202080024275.2A patent/CN113631195A/zh active Pending
- 2020-02-03 TW TW109103279A patent/TW202045209A/zh unknown
-
2024
- 2024-11-28 AU AU2024266952A patent/AU2024266952A1/en active Pending
-
2025
- 2025-01-08 JP JP2025003041A patent/JP2025061126A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022523740A5 (https=) | ||
| JP7608164B2 (ja) | 抗体－薬物コンジュゲートとｐａｒｐ阻害剤の組み合わせ | |
| TWI854573B (zh) | 藥物組合物、其用途及癌症的治療方法 | |
| JP2012509889A5 (https=) | ||
| JP2022515077A5 (https=) | ||
| TW201834695A (zh) | 共軛生物分子、醫藥組成物及方法 | |
| CN102753176B (zh) | 含有cdc7抑制剂和抗癌药的治疗组合物 | |
| JP2013520442A5 (https=) | ||
| JP2018537975A5 (https=) | ||
| JP2014515036A5 (https=) | ||
| US11224654B2 (en) | Combinations and uses thereof | |
| RU2011125518A (ru) | Антиангиогенная терапия, применяемая для лечения рака молочной железы | |
| JP2019517485A5 (https=) | ||
| JP2023517243A5 (https=) | ||
| JP2014525925A (ja) | 抗−ｃｄ１９抗体とプリン類似体の併用治療 | |
| JP2014525925A5 (https=) | ||
| TW201107327A (en) | Therapeutic combination comprising a PLK1 inhibitor and an antineoplastic agent | |
| WO2019072220A1 (zh) | Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途 | |
| JP2021530444A5 (https=) | ||
| WO2022221170A1 (en) | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent | |
| JP2024533067A5 (https=) | ||
| JP2023533937A5 (https=) | ||
| IL317199A (en) | Anti-CD19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma | |
| JP2021520804A5 (https=) | ||
| CN110831604B (zh) | 用于肿瘤治疗或预防的药物组合物、方法及其用途 |